Gyre Therapeutics (GYRE) Accumulated Depreciation & Amortization (2016 - 2025)
Gyre Therapeutics (GYRE) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $6.9 million as the latest value for Q3 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $6.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.9 million, a N/A change, with the full-year FY2024 number at $5.6 million, up 31.28% from a year prior.
- Accumulated Depreciation & Amortization was $6.9 million for Q3 2025 at Gyre Therapeutics, up from $6.4 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $21.7 million in Q4 2022 to a low of $4.3 million in Q4 2023.
- A 4-year average of $8.3 million and a median of $6.0 million in 2024 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: tumbled 80.35% in 2023, then soared 33.74% in 2025.
- Gyre Therapeutics' Accumulated Depreciation & Amortization stood at $21.7 million in 2022, then crashed by 80.35% to $4.3 million in 2023, then surged by 31.28% to $5.6 million in 2024, then grew by 23.84% to $6.9 million in 2025.
- Per Business Quant, the three most recent readings for GYRE's Accumulated Depreciation & Amortization are $6.9 million (Q3 2025), $6.4 million (Q2 2025), and $5.6 million (Q4 2024).